LNA SANTE And EUROFINS SCIENT. Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.

Financial Asset Price Forward Dividend Yield Return on Equity
LNA SANTE (LNA.PA) €20.45 2.44% 7.98%
EUROFINS SCIENT. (ERF.PA) €59.08 0.96% 7.27%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. LNA SANTE (LNA.PA)

2.44% Forward Dividend Yield and 7.98% Return On Equity

LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.

Earnings Per Share

As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.

PE Ratio

LNA SANTE has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.98%.

Yearly Top and Bottom Value

LNA SANTE’s stock is valued at €20.45 at 12:30 EST, way under its 52-week high of €31.25 and way above its 52-week low of €16.92.

Volume

Today’s last reported volume for LNA SANTE is 10198 which is 85.31% above its average volume of 5503.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LNA SANTE’s stock is considered to be oversold (<=20).

More news about LNA SANTE.

2. EUROFINS SCIENT. (ERF.PA)

0.96% Forward Dividend Yield and 7.27% Return On Equity

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

Earnings Per Share

As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.

PE Ratio

EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.27%.

Moving Average

EUROFINS SCIENT.’s value is way higher than its 50-day moving average of €50.50 and above its 200-day moving average of €55.00.

More news about EUROFINS SCIENT..

Leave a Reply

Your email address will not be published. Required fields are marked *